Viatris (VTRS) said, for combined long-term Targets through 2030, the company expects to deliver 5% to 6% total revenues CAGR, 7% to 8% adjusted EBITDA CAGR, 9% to 10% adjusted EPS CAGR and more than $3 billion in annual free cash flow in 2030.
The company said its combined long-term targets are comprised of the base case long-term targets and potential additional drivers. For base case long-term targets through 2030, Viatris expects base business, supported by anticipated upcoming launches of value-added medicines, to deliver 3% to 4% total revenues CAGR, 4% to 5% adjusted EBITDA CAGR, 6% to 7% adjusted EPS CAGR, and more than $2.7 billion in annual free cash flow in 2030. The company expects more than $11 billion in cash available for deployment through 2030 under its base case long-term targets. Potential additional drivers include expected growth from accretive business development and the potential launches of selatogrel and cenerimod.
Doretta Mistras, CFO, Viatris, said: "We expect to have more than $11 billion in cash available for deployment through 2030, which would enable us to return capital to shareholders and pursue accretive business development to further strengthen our long-term growth profile."
In pre-market trading on NasdaqGS, Viatris shares are down 3.35 percent to $13.28.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.